A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Pachyonychia Congenita

Interventions

DRUG: QTORIN 3.9% rapamycin anhydrous gel
DRUG: Vehicle

Sponsor

Palvella Therapeutics, Inc.